Clinical trials
Primary Sclerosing Cholangitis clinical trials
Below are recruiting primary sclerosing cholangitis clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02137668RecruitingPhase 1
Testing vancomycin for certain pediatric bile duct conditions
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
Sacramento, CaliforniaAges 2 weeks–40 years - NCT05618145Recruiting
Join a national study database for primary sclerosing cholangitis
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
AnconaAges 17 years+ - NCT07607353Recruiting
Biodegradable Stents for Primary Sclerosing Cholangitis
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
LondonAges 18 years+ - NCT06767605Recruiting
Spanish registry for autoimmune liver diseases
This study collects information from people with autoimmune or cholestatic liver diseases to better understand them and improve care. It does not test a new treatment, but your participation can help future research.
BarcelonaAges 18 years+ - NCT07387549RecruitingPhase 3
Elafibranor for primary sclerosing cholangitis
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
Chandler, ArizonaAges 18–75 - NCT07341282RecruitingPhase 2
Vancomycin for ulcerative colitis with liver condition
This trial tests whether the antibiotic vancomycin can help treat active ulcerative colitis in people who also have primary sclerosing cholangitis (a liver condition). Vancomycin may reduce inflammation in the gut by changing the bacteria in your intestines.
Hamilton, OntarioAges 18 years+ - NCT07229911RecruitingPhase 1
Study of TAK-781 in healthy people and PSC patients
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
Salt Lake City, UtahAges 18–68 - NCT05295680RecruitingPhase 2
Oral hymecromone for primary sclerosing cholangitis
This trial tests whether taking hymecromone by mouth can improve primary sclerosing cholangitis (a liver/bile duct condition). It may help by targeting inflammation and bile duct problems, especially in people who are stable on other medicines.
Redwood City, CaliforniaAges 14–75 - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT03146936Recruiting
Study of people with primary sclerosing cholangitis in Switzerland
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
Lugano, Canton TicinoAges Any age - NCT06286709RecruitingPhase 2
Fecal transplant for PSC and colitis
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
BirminghamAges 18 years+ - NCT05912387RecruitingEarly Phase 1
Testing statin treatment in primary sclerosing cholangitis
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Stanford, CaliforniaAges 18–80 - NCT04685200Recruiting
Study causes of primary sclerosing cholangitis using body scans
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Bethesda, MarylandAges 18–90 - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Los Angeles, CaliforniaAges 2–25 - NCT03445585Recruiting
Biobank study for primary sclerosing and primary biliary cholangitis
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Rochester, MinnesotaAges 18–85 - NCT06016842RecruitingPhase 3
Long-term study of elafibranor for primary biliary cholangitis
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Tucson, ArizonaAges 18 years+ - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT07449793Recruiting
PBC treatment response and long-term health outcomes
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06865924Recruiting
Understanding genetic causes in atypical PSC using liver cells
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
Milan, MIAges 18–90 - NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75 - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Primary Sclerosing Cholangitis trials by city
Studies with a site in or near these metro areas.
Primary Sclerosing Cholangitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for primary sclerosing cholangitis?
- Yes. Clin2 currently lists 37 recruiting primary sclerosing cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary sclerosing cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary sclerosing cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.